Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Qilu Pharmaceutical Co., Ltd.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
1\. Histological or cytological diagnosis of prostate cancer;；
Advanced prostate cancer patients eligible for endocrine therapy, able to receive continuous androgen deprivation therapy for at least 6 months.
Serum testosterone ≥150 ng/dL (5.2nmol/L) at screening visit;
The Eastern Cooperative Oncology Group (ECOG) score is 0 to 1.
You may not be if
Diagnosed or suspected of hormone-resistant prostate cancer;
For prostate cancer patients who have had or are undergoing endocrine therapy
Patients who have previously undergone pituitectomy or adrenalectomy or have pituitary disease or adrenal dysfunction;
Those who have had any prostate surgery within 4 weeks prior to initial dosing or prostate surgery or other major surgical treatment during the planned trial period (except urinary tract obstruction relief);
The imaging results of screening visits clearly showed the presence of brain metastases;
